FDA Approves Garetosmab for Fibrodysplasia Ossificans Progressiva
Source Summary
The FDA approved garetosmab (Pasatru), a monoclonal antibody activin signaling inhibitor, to reduce the formation of new heterotopic ossification lesions and disease flares in adults with fibrodysplasia ossificans progressiva (FOP).
